A large French prospective cohort of HIV‐infected patients: the Nadis Cohort

Abstract

The aim of this article is to describe the development of a dynamic French cohort of HIV-infected patients, the methodological issues and decisions made, and the characteristics of the patients currently enrolled. MethodsData are collected during medical encounters. Data quality is ensured by automated checks during data capture, by regular controls, by annual assessments, and by ad hoc processes before any scientific analysis is performed. ResultsIn September 2007, 10 458 patients representing 59 383 patient-years of follow-up were followed in our centres, including 446 with a first HIV diagnosis in the past year. Among these recently diagnosed patients, 25.6% presented with late diagnosis. Our cohort included 3017 women (28.8%). The women were less likely to be receiving highly active antiretroviral therapy (HAART) than men, and when treated were less likely to be receiving nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. Our network includes medical centres in overseas territories (1105 patients living overseas). In this particular population, women represented 38.5% of the patients, and the probable route of infection was heterosexual in 75.7% of the patients. Despite epidemiological and social disparities, more patients had nondetectable viral loads when receiving HAART in overseas departments than in metropolitan France. ConclusionThe Nadis Cohort represents a collaboration of major French HIV treatment centres. In September 2007, the cohort database contained up-to-date information on more than 10 000 patients, of whom a significant proportion were women. As a consequence of the choices made when building the cohort and the efforts made to ensure the quality of the database, scientific studies are regularly performed using this cohort.

Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥60 ml/min per 1.73 m2

“…All patients enrolled had at least one consultation in the Department of Infectious Diseases during the study period, with a standardized biological assessment (blood and urine) and were included in a computerized medical record (e-NADIS) [17], after receiving verbal information and giving written consent. The study was approved by the local ethic committee and was declared under the number DC-2012-1579 to be in accordance with French law.…”

Impact of hepatitis C virus coinfection on T-cell dynamics in long-term HIV-suppressors under combined antiretroviral therapy

“…Data of patients under cART who achieved undetectable HIV-pVL for at least 3 years were collected from our electronic database, NADIS (Fedialis Medica, Marly le Roi, France) [7,8] from January 1997 to April 2005. This period was defined in order to select patients who were naive of interferon (IFN)-based hepatitis treatment.…”

Risk Factors of Chronic Kidney Disease in HIV-infected Patients

“…The study design was approved by the Nadis scien- (18). The patients enter the cohort when they seek care in one of the centers, regardless of their HIV disease history, and all previous clinical events as well as therapeutic history are collected with appropriate dates.…”